


Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL_programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1003 of 1628 alation vs. old formulation

Page 30 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1003/1628

M


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1004 of 1628 alation vs. old formulation

Page 31 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900bab8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1004/1628



Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



0:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Levothyroxine
EMR 200125-001


Bioequiv EMR200125-001 Page 1007 of 1628 alation vs. old formulation

Page 34 of 216
Confidential

Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1007/1628

M


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1008 of 1628 nlation vs. old formulation

Page 35 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1008/1628

W


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1009 of 1628 alation vs. old formulation

Page 36 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1009/1628

M


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1010 of 1628 nlation vs. old formulation

Page 37 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900bab8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1010/1628

WV

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1012 of 1628 nlation vs. old formulation

Page 39 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1012/1628

AVI

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: :



◊:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1014 of 1628 nlation vs. old formulation

Page 41 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1014/1628

AM

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014_00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1017 of 1628 alation vs. old formulation

Page 44 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE 15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1017/1628

UVI


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1018 of 1628 niation vs. old formulation

Page 45 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1...



⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1018/1628

8M

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014_00-01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1020 of 1628 uation vs. old formulation

Page 47 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1020/1628

AVU

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



④: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sas

11DEC2014 00:01


**Levothyroxine
EMR 200125-001**

Bioequiv EMR200125-001 Page 1022 of 1628 nlation vs. old formulation

Page 49 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1022/1628

AVI

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01


**Levothyroxine
EMR 200125-001**

Bioequiv EMR200125-001 Page 1024 of 1628 nlation vs. old formulation

Page 51 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



④: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1024/1628



Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: /




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1027 of 1628 uation vs. old formulation

Page 54 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1027/1628

M

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1029 of 1628 ulation vs. old formulation

Page 56 of 216
Confidential

Merc Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1029/1628

WV


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1030 of 1628 nlation vs. old formulation

Page 57 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1030/1628

M


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1031 of 1628 alation vs. old formulation

Page 58 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



0:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1031/1628

M

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1034 of 1628 nlation vs. old formulation

Page 61 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1034/1628

AM

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



0:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Levothyroxine
EMR 200125-001


Bioequiv EMR200125-001 Page 1037 of 1628 alation vs. old formulation

Page 64 of 216

Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: :



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1037/1628

IV


Levothyroxine
EMR 200125-001

Bioequiv **EMR200125-001 Page 1038 of 1628** nulation vs. old formulation

Page 65 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



④: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1038/1628

M

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1040 of 1628 nlation vs. old formulation

Page 67 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1040/1628

WV

Levothyroxine
EMR 200125-001


Bioequiv EMR200125-001 Page 1041 of 1628 alation vs. old formulation

Page 68 of 216

Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1041/1628

AM


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1042 of 1628 alation vs. old formulation

Page 69 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: -



⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1042/1628

01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1044 of 1628 nlation vs. old formulation

Merck Serono


EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:

Page 71 of 216

Confidential



① Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1044/1628

IV

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Levothyroxine
EMR 200125-001


Bioequiv EMR200125-001 Page 1046 of 1628 alation vs. old formulation

Page 73 of 216

Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1046/1628

M

Levothyroxine
EMR 200125-001


Bioequiv EMR200125-001 Page 1047 of 1628 uation vs. old formulation

Page 74 of 216
Confidential

Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number: 1



⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1047/1628

MV

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1049 of 1628 alation vs. old formulation

Page 76 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: ? 1113



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1049/1628

MM


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1050 of 1628 ualation vs. old formulation

Page 77 of 216
Confidential

March Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1050/1628

M

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1052 of 1628 alation vs. old formulation

Page 79 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1052/1628

WV

Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1053 of 1628 alation vs. old formulation


Page 80 of 216
Confidential

Merck Serono

EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



◊:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1053/1628

M


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1054 of 1628 nlation vs. old formulation

Page 81 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



①: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TEF programs/Figures/Figure 15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1054/1628

IV


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1055 of 1628 alation vs. old formulation

Page 82 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/TFL programs/Figures/Figure 15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1055/1628

M


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1056 of 1628 nlation vs. old formulation

Page 83 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 11124



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1056/1628

8M


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1057 of 1628 alation vs. old formulation

Page 84 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1057/1628

M


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1058 of 1628 nlation vs. old formulation

Page 85 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: :



①: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1060 of 1628 alation vs. old formulation

Page 87 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1063 of 1628 alation vs. old formulation

Page 90 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



⑥:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1063/1628

WV

Levothyroxine
EMR 200125-001


Bioequiv EMR200125-001 Page 1064 of 1628 nulation vs. old formulation

Page 91 of 216

Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1064/1628



Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



#:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.3.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014_00:01

Merci Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1068 of 1628 ualation vs. old formulation

Page 95 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



①: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1068/1628

IV

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1070 of 1628 nulation vs. old formulation

Page 97 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1070/1628

W

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1




⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGures/Figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1074 of 1628 alation vs. old formulation

Page 101 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1074/1628

AVI


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1075 of 1628 alation vs. old formulation

Page 102 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



#:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1075/1628

M

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGures/Figure
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1077 of 1628 nulation vs. old formulation

Page 104 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1077/1628

AM
PM


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1078 of 1628 nlation vs. old formulation

Page 105 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: :



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL_programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1078/1628

M


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1079 of 1628 alation vs. old formulation

Page 106 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGures/FIGure
15.4.2.10.sas

11DEC2014 00:01

Document No 0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1079/1628

M
W

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



①: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1081 of 1628 alation vs. old formulation

Page 108 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1 1081



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1081/1628

M


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1082 of 1628 alation vs. old formulation

Page 109 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number: : 6




⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1084 of 1628 alation vs. old formulation

Page 111 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1085 of 1628 alation vs. old formulation

Page 112 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1085/1628

M
VV

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing, 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Levothyroxine
EMR 200125-001


Bioequiv EMR200125-001 Page 1087 of 1628 alation vs. old formulation

Page 114 of 216

Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: :



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1087/1628

AVI
UVI


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1088 of 1628 nlation vs. old formulation

Page 115 of 216
Confidential

Merci Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T₄ Values) (Safety Population)

Subject ID/Random Number: 1 200



①: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1088/1628

MM


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1089 of 1628 alation vs. old formulation

Page 116 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: ..



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1089/1628

MM

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1091 of 1628 uation vs. old formulation

Page 118 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.1.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014_00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1092 of 1628 alation vs. old formulation

Page 119 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



⑥: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014_00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1092/1628

8M


**Levothyroxine
EMR 200125-001**

Bioequiv EMR200125-001 Page 1093 of 1628 alation vs. old formulation

Page 120 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



#:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1093/1628

M

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1095 of 1628 alation vs. old formulation

Page 122 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1096 of 1628 uation vs. old formulation

Page 123 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



④ Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/FIGURES/FIGURE
15.4.2.10.sas

11DEC2014 00:01

Document No.0900bab8085bb46 v1.0


CONFIDENTIAL
INFORMATION

1096/1628

W

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01


Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 1098 of 1628 nlation vs. old formulation

Page 125 of 216
Confidential

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: J



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
15.4.2.10.sas

11DEC2014 00:01

Document No.0900babe8085bb46 v1.0

CONFIDENTIAL
INFORMATION

1098/1628

MM